{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:07:11Z","timestamp":1789675631189,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Transarterial radioembolization (TARE) with Yttrium-90 resin microspheres is a treatment option for patients with intrahepatic cholangiocarcinoma (ICC). However, optimising the timing of TARE in relation to systemic therapies and patient selection remains challenging. We report here on the effectiveness, safety, and prognostic factors associated with TARE for ICC in a combined analysis of the prospective observational CIRT studies (NCT02305459 and NCT03256994).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A combined analysis of 174 unresectable ICC patients enrolled between 2015 and 2020 was performed. Patient characteristics and treatment-related data were collected at baseline; adverse events and time-to-event data (overall survival [OS], progression-free survival [PFS] and hepatic PFS) were collected at every follow-up visit. Log-rank tests and a multivariable Cox proportional hazard model were used to identify prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients receiving a first-line strategy of TARE in addition to any systemic treatment had a median OS and PFS of 32.5\u00a0months and 11.3\u00a0months. Patients selected for first-line TARE alone showed a median OS and PFS of 16.2\u00a0months and 7.4\u00a0months, whereas TARE as 2nd or further treatment-line resulted in a median OS and PFS of 12 and 9.3\u00a0months (p\u2009=\u20090.0028), and 5.1 and 3.5\u00a0months (p\u2009=\u20090.0012), respectively. Partition model dosimetry was an independent predictor for better OS (HR 0.59 [95% CI 0.37\u20130.94], p\u2009=\u20090.0259). No extrahepatic disease, no ascites, and\u2009&lt;\u20096.1\u00a0months from diagnosis to treatment were independent predictors for longer PFS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This combined analysis indicates that in unresectable ICC, TARE in combination with any systemic treatment is a promising treatment option.<\/jats:p>\n                <jats:p><jats:bold>Level of evidence<\/jats:bold>: level 3, Prospective observational<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00270-023-03657-x","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T17:39:28Z","timestamp":1707241168000},"page":"310-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies"],"prefix":"10.1007","volume":"47","author":[{"given":"Peter","family":"Reimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Vilgrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugsan","family":"Balli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Golfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romaric","family":"Loffroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Maleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Munneke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Peynircioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Urdaniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-2973","authenticated-orcid":false,"given":"Niels","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helmberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"issue":"5","key":"3657_CR1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261\u201380.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"3657_CR2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755\u201362.","journal-title":"Ann Surg"},{"key":"3657_CR3","doi-asserted-by":"crossref","unstructured":"Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463\u201373; discussion 73\u20135.","DOI":"10.1097\/00000658-199610000-00005"},{"issue":"1","key":"3657_CR4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104\u201314.","journal-title":"J Hepatol"},{"issue":"suppl 5","key":"3657_CR5","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28\u201337.","journal-title":"Ann Oncol"},{"key":"3657_CR6","doi-asserted-by":"crossref","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(5):541\u201365.","DOI":"10.6004\/jnccn.2021.0022"},{"issue":"9","key":"3657_CR7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"3657_CR8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/0284186X.2019.1590634","volume":"58","author":"M Strijker","year":"2019","unstructured":"Strijker M, Belkouz A, van der Geest LG, van Gulik TM, van Hooft JE, de Meijer VE, et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol. 2019;58(7):1048\u201355.","journal-title":"Acta Oncol"},{"issue":"6","key":"3657_CR9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","volume":"221","author":"B Groot Koerkamp","year":"2015","unstructured":"Groot Koerkamp B, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221(6):1041\u20139.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"3657_CR10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","volume":"273","author":"WA Cambridge","year":"2021","unstructured":"Cambridge WA, Fairfield C, Powell JJ, Harrison EM, Soreide K, Wigmore SJ, et al. Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma. Ann Surg. 2021;273(2):240\u201350.","journal-title":"Ann Surg"},{"issue":"1","key":"3657_CR11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.hpb.2017.08.025","volume":"20","author":"JLA van Vugt","year":"2018","unstructured":"van Vugt JLA, Gaspersz MP, Coelen RJS, Vugts J, Labeur TA, de Jonge J, et al. The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma. HPB (Oxford). 2018;20(1):83\u201392.","journal-title":"HPB (Oxford)"},{"issue":"4","key":"3657_CR12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469\u201374.","journal-title":"Br J Cancer"},{"issue":"14","key":"3657_CR13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"10391","key":"3657_CR14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet."},{"key":"3657_CR15","doi-asserted-by":"crossref","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence. 2022;1(8).","DOI":"10.1056\/EVIDoa2200015"},{"issue":"5","key":"3657_CR16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3657_CR17","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","volume":"22","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22(11):1560\u201372.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3657_CR18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450116666150223121508","volume":"18","author":"JJG Marin","year":"2017","unstructured":"Marin JJG, Lozano E, Briz O, Al-Abdulla R, Serrano MA, Macias RIR. Molecular bases of chemoresistance in cholangiocarcinoma. Curr Drug Targets. 2017;18(8):889\u2013900.","journal-title":"Curr Drug Targets"},{"issue":"4 Pt B","key":"3657_CR19","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.bbadis.2017.06.005","volume":"1864","author":"JJG Marin","year":"2018","unstructured":"Marin JJG, Lozano E, Herraez E, Asensio M, Di Giacomo S, Romero MR, et al. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1444\u201353.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3657_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102258","volume":"99","author":"J Edeline","year":"2021","unstructured":"Edeline J, Lamarca A, McNamara MG, Jacobs T, Hubner RA, Palmer D, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev. 2021;99: 102258.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"3657_CR21","doi-asserted-by":"crossref","DOI":"10.2196\/16296","volume":"9","author":"T Helmberger","year":"2020","unstructured":"Helmberger T, Arnold D, Bilbao JI, de Jong N, Maleux G, Nordlund A, et al. Clinical application of radioembolization in hepatic malignancies: protocol for a prospective multicenter observational study. JMIR Res Protoc. 2020;9(4): e16296.","journal-title":"JMIR Res Protoc"},{"key":"3657_CR22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","volume":"44","author":"T Helmberger","year":"2021","unstructured":"Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for sir-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44:21\u201335.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3657_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00270-020-02643-x","volume":"44","author":"R Loffroy","year":"2021","unstructured":"Loffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, et al. Short-term safety and quality of life outcomes following radioembolization in primary and secondary liver tumours: a multi-centre analysis of 200 patients in France. Cardiovasc Intervent Radiol. 2021;44:36\u201349.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3657_CR24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clcc.2022.09.002","volume":"21","author":"N Schaefer","year":"2022","unstructured":"Schaefer N, Gr\u00f6zinger G, Pech M, Pfammatter T, Soydal C, Arnold D, et al. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022;21:285\u201396.","journal-title":"Clin Colorectal Cancer"},{"key":"3657_CR25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00270-023-03391-4","volume":"46","author":"G Maleux","year":"2023","unstructured":"Maleux G, Albrecht T, Arnold D, Bargellini I, Cianni R, Helmberger T, et al. Predictive factors for adverse event outcomes after transarterial radioembolization with yttrium-90 resin microspheres in Europe: results from the prospective observational CIRT study. Cardiovasc Intervent Radiol. 2023;46:852\u201367.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"3657_CR26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/RLU.0000000000000904","volume":"40","author":"J Edeline","year":"2015","unstructured":"Edeline J, Du FL, Rayar M, Rolland Y, Beuzit L, Boudjema K, et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med. 2015;40(11):851\u20135.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"3657_CR27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/bjc.2016.191","volume":"115","author":"C Mosconi","year":"2016","unstructured":"Mosconi C, Gramenzi A, Ascanio S, Cappelli A, Renzulli M, Pettinato C, et al. Yttrium-90 radioembolization for unresectable\/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. 2016;115(3):297\u2013302.","journal-title":"Br J Cancer"},{"issue":"11","key":"3657_CR28","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jvir.2021.08.009","volume":"32","author":"A Sarwar","year":"2021","unstructured":"Sarwar A, Ali A, Ljuboja D, Weinstein JL, Shenoy-Bhangle AS, Nasser IA, et al. Neoadjuvant Yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2021;32(11):1560\u20138.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"3657_CR29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/liv.13382","volume":"37","author":"A Cucchetti","year":"2017","unstructured":"Cucchetti A, Cappelli A, Mosconi C, Zhong JH, Cescon M, Pinna AD, et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study. Liver Int. 2017;37(7):1056\u201364.","journal-title":"Liver Int"},{"issue":"1","key":"3657_CR30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):51\u20139.","journal-title":"JAMA Oncol"},{"key":"3657_CR31","doi-asserted-by":"crossref","unstructured":"Robinson TJ, Du L, Matsuoka L, Sze DY, Kennedy AS, Gandhi RT, et al. Survival and toxicities after yttrium-90 transarterial radioembolization of cholangiocarcinoma in the RESiN registry. J Vasc Interv Radiol. 2022;34(4):694\u2013701.e3.","DOI":"10.1016\/j.jvir.2022.10.042"},{"issue":"4","key":"3657_CR32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2967\/jnumed.122.264598","volume":"64","author":"BM Schaarschmidt","year":"2022","unstructured":"Schaarschmidt BM, Kloeckner R, Dertnig T, Demircioglu A, Muller L, Auer TA, et al. Real-life experience in the treatment of intrahepatic cholangiocarcinoma by (90)Y radioembolization: a multicenter retrospective study. J Nucl Med. 2022;64(4):529\u201335.","journal-title":"J Nucl Med"},{"issue":"5","key":"3657_CR33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11523-022-00906-w","volume":"17","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Bibeau K, Schultz N, Yaqubie A, Millang B, Ren H, et al. Effect of FGFR2 alterations on overall and progression-free survival in patients receiving systemic therapy for intrahepatic cholangiocarcinoma. Target Oncol. 2022;17(5):517\u201327.","journal-title":"Target Oncol"},{"key":"3657_CR34","volume":"6","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Feliz L, Lihou CF, Ren H, Abou-Alfa GK. Progression-free survival in patients with cholangiocarcinoma with or without FGF\/FGFR alterations: a FIGHT-202 post hoc analysis of prior systemic therapy response. JCO Precis Oncol. 2022;6: e2100414.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"3657_CR35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3657_CR36","doi-asserted-by":"crossref","unstructured":"Garin E, Tzelikas L, Guiu B, Chalaye J, Edeline J, Baere TD, et al. Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: Final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01). J Clin Oncol. 2020;38(4_suppl):516.","DOI":"10.1200\/JCO.2020.38.4_suppl.516"},{"issue":"2","key":"3657_CR37","volume":"5","author":"F Kolligs","year":"2023","unstructured":"Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, et al. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study. JHEP Rep. 2023;5(2): 100633.","journal-title":"JHEP Rep"},{"issue":"5","key":"3657_CR38","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","volume":"48","author":"H Levillain","year":"2021","unstructured":"Levillain H, Bagni O, Deroose CM, Dieudonne A, Gnesin S, Grosser OS, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"3657_CR39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MNM.0000000000001345","volume":"42","author":"B Cheng","year":"2021","unstructured":"Cheng B, Sethi I, Davisson N, Brandon D, Barron B, Galt J, et al. Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer. Nucl Med Commun. 2021;42(4):402\u20139.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"3657_CR40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","volume":"44","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Solaini L, Vara G, Brandi N, Cappelli A, Modestino F, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis. Cardiovasc Intervent Radiol. 2021;44(5):728\u201338.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"3657_CR41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jvir.2022.02.016","volume":"33","author":"DA Schartz","year":"2022","unstructured":"Schartz DA, Porter M, Schartz E, Kallas J, Gupta A, Butani D, et al. Transarterial yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol. 2022;33(6):679\u201386.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"3657_CR42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000516880","volume":"10","author":"Q Yu","year":"2021","unstructured":"Yu Q, Liu C, Pillai A, Ahmed O. Twenty years of radiation therapy of unresectable intrahepatic cholangiocarinoma: internal or external? A systematic review and meta-analysis. Liver Cancer. 2021;10(5):433\u201350.","journal-title":"Liver Cancer"},{"issue":"5","key":"3657_CR43","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"3657_CR44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jvir.2018.04.001","volume":"29","author":"A Gangi","year":"2018","unstructured":"Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, et al. Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interv Radiol. 2018;29(8):1101\u20138.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3657_CR45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","volume":"35","author":"RT Hoffmann","year":"2012","unstructured":"Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105\u201316.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"3657_CR46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jvir.2013.02.031","volume":"24","author":"S Mouli","year":"2013","unstructured":"Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227\u201334.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"3657_CR47","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","volume":"36","author":"S Rafi","year":"2013","unstructured":"Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"3657_CR48","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00270-017-1871-2","volume":"41","author":"P Reimer","year":"2018","unstructured":"Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schon MR, Tatsch K. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-naive patients. Cardiovasc Intervent Radiol. 2018;41(5):744\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"3657_CR49","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jvir.2019.03.018","volume":"30","author":"J White","year":"2019","unstructured":"White J, Carolan-Rees G, Dale M, Patrick HE, See TC, Bell JK, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational study. J Vasc Interv Radiol. 2019;30(8):1185\u201392.","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"3657_CR50","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","volume":"43","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Mosconi C, Pizzi G, Lorenzoni G, Vivaldi C, Cappelli A, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol. 2020;43(9):1305\u201314.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"3657_CR51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/jcm9010056","volume":"9","author":"M Kohler","year":"2019","unstructured":"Kohler M, Harders F, Lohofer F, Paprottka PM, Schaarschmidt BM, Theysohn J, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9(1):56.","journal-title":"J Clin Med."},{"issue":"5","key":"3657_CR52","first-page":"161","volume":"32","author":"NC Swinburne","year":"2017","unstructured":"Swinburne NC, Biederman DM, Besa C, Tabori NE, Fischman AM, Patel RS, et al. Radioembolization for unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival. Cancer Biother Radiopharm. 2017;32(5):161\u20138.","journal-title":"Cancer Biother Radiopharm."},{"issue":"1","key":"3657_CR53","first-page":"91","volume":"7","author":"WN Dudley","year":"2016","unstructured":"Dudley WN, Wickham R, Coombs N. An Introduction to Survival Statistics: Kaplan-Meier Analysis. J Adv Pract Oncol. 2016;7(1):91\u2013100.","journal-title":"J Adv Pract Oncol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-023-03657-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T22:02:20Z","timestamp":1710108140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-023-03657-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["3657"],"URL":"https:\/\/doi.org\/10.1007\/s00270-023-03657-x","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Val\u00e9rie Vilgrain recieved payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, and payment for expert testimony from Sirtex. Dirk Arnold received consulting fees and honoraria for presentations and lectures and travel support from Boston Scientific and Terumo, MSD, BMS, AstraZeneca, Roche, Servier, Sanofi and Merck Serono. He is on the guidelines committee of the European Society for Medical Oncology, and supported oncopolicy manuscripts for the European Cancer Organisation. Maxime Ronot received honoraria for lectures from GE Healthcare, Ipsen, Canon-Toshiba, Alexion Pharmaceuticals, Guerbet, and Sirtex. Geert Maleux received honoraria for speaker\u2019s bureau from Sirtex Medical and operated as a proctor for Sirtex. Bruno Sangro received grants or contracts from Sirtex and BMS, consulting fees from Adaptimmune, Astra Zeneca, Bayer, BMS, Boston Scientific, Eisai, Eli Lilly, Incyte, Ipsen, Roche, Sirtex Medical, Terumo; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Roche, Sirtex Medical; Participation on a Data Safety Monitoring Board or Advisory Board from Adaptimmune, Astra Zeneca, Bayer, BMS, Boston Scientific, Eisai, Eli Lilly, Incyte, Ipsen, Roche, Sirtex Medical, Terumo, and has a leadership or fiduciary role in the International Liver Cancer Association. Peter Reimer, Tugsan Balli, Rita Golfieri, Romaric Loffroy, Cristina Mosconi, Christian Sengel, Niklaus Schaefer, Graham Munneke, Bora Peynircioglu, Nathalie Kaufmann, Maria Urdaniz, Helena Pereira, Niels de Jong and Thomas Helmberger had nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study has been approved by applicable ethics committees. All participants signed an informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}